Biologics CDMO Market Size & Analysis Report | Increase at a CAGR of 14% to 16% by 2029

The Global Biologics CDMO Market is expected to grow at a rate of between 14-16% over the coming five years. The market for biopharmaceuticals is growing, the complexity of biologics forcing pharmaceutical firms to outsource their work, growing number of biologics being created by biotechs that are small and virtual growing biopharma industry for smaller biopharma companies in China and supported by a an abundance of financing as well as favorable changes to the regulatory environment are just a few of the major factors driving Biologics CDMO market's expansion. However, the expense of producing Regenerative medicines is one of the major obstacles in the way to commercialization. Reluctance to outsource IP/know-how to pharma companies and capacity/scalability issues due to the complicated nature of biologics are just a few of the factors that are likely to impede the growth of the market.

The Biologics CDMO market comprises organizations that offer development and manufacturing solutions for biologics. Biologics CDMOs aid biotech and pharmaceutical businesses by providing expert knowledge and modern facilities to produce biologic therapies, which include monoclonal antibodies as well as gene and cell treatments, vaccines as well as Recombinant proteins.

Explore market trends, size, share and growth report - request a sample copy:
https://meditechinsights.com/global-biologics-cdmo-market/request-sample/

Growing Biopharmaceuticals Market to Drive Market Growth

The market for biopharmaceuticals is rapidly expanding due to the growing prevalence of chronic diseases, advances in biotechnology and the increasing demand for personalized medical treatment. This is directly impacting the biologics CDMO market. CDMOs for biologics offer special services, including manufacturing, drug development and regulatory assistance vital for biopharmaceutical companies seeking to introduce complex biologics swiftly and cost-effectively. As biopharmaceutical firms face increasing pressure to speed up the development process and improve production, they are increasingly outsourcing to CDMOs to benefit from their expertise and the latest technologies. In addition, the growing demand for biologics, including monoclonal antibodies as well as gene and cell therapies and recombinant proteins requires advanced manufacturing capabilities, which CDMOs provide. Thus, the growing biopharmaceuticals market is driving the need for biologic CDMO services, thereby facilitating the growth of the market and fostering innovation within the industry.

"As pharmaceutical and biotech companies seek to bring innovative biologics to market, they are increasingly turning to CDMOs to leverage specialized expertise, state-of-the-art technologies, and cost-effective solutions"

- Senior Director, A Global Leading CMO, United States

The complexity of biologics is increasing to drive Market Growth

Advanced biologics, such as gene and cell therapies require specialized knowledge and cutting-edge technology to make. CDMOs provide the required expertise and facilities that are up-to-date that allow for quicker development and production times. Through the use of CDMO capabilities companies can reduce the risks associated with the production of biologics including scaling and compliance with regulatory requirements. Pharma companies can focus on their core business such as research and development while CDMOs manage complicated manufacturing processes. Biopharmaceutical companies typically do not have the expertise and infrastructure needed to develop and produce these innovative treatments. This is why they are looking to CDMOs for their expertise, modern facilities, and the capability to scale production effectively. CDMOs provide a variety of services, ranging from early-stage development to commercial-scale manufacturing which allows biopharmaceutical companies to develop complex biologics faster and efficiently. Additionally, the adoption of advanced technologies, such as automated manufacturing, data-driven manufacturing and single-use systems, by CDMOs increases their ability to manage the complexity of manufacturing biologics. These technologies enhance efficiency and reduce human error and allow for rapid adapting to the changing demands of production.

As demand for novel biologics continues to increase CDMOs' role in providing the required expertise and infrastructure will grow more important, resulting in substantial growth in the biologics CDMO market

Rising Number of Biologics in the Pipeline are Driving the Biologics CDMO Market

With an increasing emphasis on new treatments, including monoclonal antibody, gene therapies and recombinant proteins, biopharmaceutical firms are pushing a growing array of biologics through different phases of clinical trials. The rapid development of biologics requires the use of specialized manufacturing capabilities which many companies do not have in-house. CDMOs offer essential services, such as manufacturing, development and regulatory support which allows biopharmaceutical companies to effectively advance their biologics from preclinical stage to commercialization. The complexity of biologics manufacturing, which involves advanced technologies and strict regulations, also makes companies look for CDMO collaborations. In addition the trend towards personalized medical treatments and targeted therapies increases the demand for scalable and flexible manufacturing solutions that CDMOs provide which is boosting the growth of the market. The growing pipeline of biologics results in a strong demand for the specialist expertise and infrastructure offered by CDMOs, pushing the market forward

US Expected to be a Major Growth Engine in Biologics CDMO Market

The US is expected to be an important driver of growth within the biologics CDMO market due to a number of important factors. The robust biopharmaceutical sector in the US which is characterized by large R&D investments as well as a significant number of biotech companies, creates demand for manufacturing services for biologics. In addition the US has an advanced technology and infrastructure that is crucial to manufacturing biologics. Support for regulatory requirements, such as the FDA's simplified approval processes also boosts the growth of the market. The increasing incidence of chronic diseases requires the development of the development of new biologic therapies, which increases the demand for CDMO services. Strategic collaborations between CDMOs and biopharma companies help in the rapid production and distribution of biologics. The US market's overall growth is also driven by a highly skilled workforce as well as extensive clinical research as well as a strong intellectual property system, which makes it a major participant in the international biologics CDMO landscape.

Product Type Segment Analysis

Monoclonal antibody (mAbs) hold the largest part of the biologics CDMO market because of their proven effectiveness and widespread use in treating a variety of illnesses, including those with autoimmune conditions, cancer as well as infectious diseases. Their ability to identify and neutralize pathogens or malignant cells has made them an essential component in treatment regimens. In addition, advances in mAb production techniques and the increase in regulatory approvals have helped boost their market dominance.

On the other side the gene and cell therapy CDMO market is anticipated to experience the fastest growth due to the revolutionary potential of these therapies to treat previously untreatable genetic diseases and complex diseases. The growing amount of clinical trials, the substantial investment in R&D and the successful commercialization of gene and cell therapies are fueling the rapid expansion. Additionally, advances in gene editing technologies like CRISPR and the increasing need for personalized medicine have contributed to the rapid expansion of the gene therapy and cell therapy CDMO market.

Application Type Scale of Operation Analysis

The Biologics CDMO market can be evaluated according to scale of operation like Pre-clinical, Clinical scale of operation. Commercial scale of operation is the most significant and fastest growing segment in the biologics CDMO market. The dominant position of this segment is fueled by the growing number of biologics that have received commercial approval and the consequent demand for large-scale production. The escalating demands for biologics, which includes monoclonal antibodies and vaccines, and gene and cell therapies requires extensive manufacturing capabilities to meet market demands. In addition, the commercial sector has the benefit of long-term contracts for manufacturing, which ensure steady income streams for CDMOs. Rapid growth in this segment is driven by technological advancements in biomanufacturing processes such as single-use technology as well as continuous manufacturing that increase productivity and scaling. The increasing prevalence of chronic illness and the increasing emphasis on personalized medicine boost the need commercially-scale biologics production. In addition, CDMOs are investing in expanding their capacity for commercial production to meet the increasing demand of biologics, which is accelerating the rapid growth of this sector.

Competitive Landscape Analysis: Biologics CDMO Market

The world Biologics CDMO market is characterized by the presence of reputable market players like Lonza, Catalent, Wuxi Biologics, Samsung Biologics, Fujifilm, Boehringer Ingelheim, Fusion Pharma, Patheon, AGC Bilogics, Eurofins CDMO and Abbvie. There are many more.

Request for TOC and Competitive Analysis: https://meditechinsights.com/global-biologics-cdmo-market/

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Market

Companies operating in this market are adopting organic and inorganic growth strategies, such as acquisitions, expansions and even acquisitions to increase market share. For instance,

In July 2024: Agilent Technologies acquired Biovectra for USD 925 million in order to increase the company's CDMO capabilities in biologics, extremely potent APIs, as well as technologies for editing genes. This acquisition will broaden Agilent's services and increase its position in the gene therapy and biologics markets.

In March 2022: Lonza signed an agreement with Roche's GenentechVacaville facility in exchange for USD 1.2 billion, which significantly increased the capacity of its large-scale biologics manufacturing. The deal, which is expected to close in the latter half of 2024, will increase the capabilities of Lonza's production and create an important West Coast manufacturing hub.

In January 2024: AGC Biologics expanded its presence in Japan by building a brand new 10,000-square-meter facility in Yokohama which is scheduled to open in 2026. It will be used to aid in the preclinical and commercial production of a variety of biologics. The US$ 350 million investment funded by Japan's METI hopes to boost the production of vaccines in Japan and expand AGC's global CDMO network.

In May 2023: Aurigene Pharmaceutical Services Limited invested USD 40 million to construct an R&D as well as a pilot-scale facility in Hyderabad, India for therapeutic proteins as well as antibodies and vectors of viral. The facility will improve their capabilities in the development of biologics and provide comprehensive services from research and development to commercial manufacturing and plans to double their global reach by 2030.

The Biologics CDMO market is expected to continue to grow in the next few years due to technological advancements, increasing R&D investments as well as new service launches as well as aggressive growth strategies both organic and inorganic being followed by the major players.

Future Outlook of the Biologics CDMO Market

The worldwide Biologics CDMO market is predicted to expand in the coming years due the increasing attention paid to biologics, innovations in biologic and biopharmaceutical R&D and advancements in manufacturing technology. These factors all contribute to the development and growth of the Biologics CDMO market.

Key Strategic Questions Addressed

What is the market size and projections for the Global Biologics CDMO Market?
What are the historical, current and forecasted market share and growth rates for various segments and sub-segments in the Global Biologics CDMO Market?
What has COVID-19 done to the Global Biologics CDMO Market?
What are the major growth drivers, restraints/challenges impacting the market?
What are the potential opportunities in the marketplace?
What is the investment landscape?
Which region is home to the largest percentage of the market globally? Which region is predicted to see the fastest growth rate over the next five years?
Who are the main players in the market? What is the competition position of the major players?
What are the latest players that are entering the market?
What are the main strategies that players employ?

Find more related report:

Biopharmaceuticals Market: https://meditechinsights.com/biopharmaceuticals-market/

Biologics Consulting Services Market: https://meditechinsights.com/biologics-consulting-services-market/

Biologics Market: https://meditechinsights.com/biologics-market/

Contact:

Ruta Halde
Associate, Medi-Tech Insights
Phone: +32 498 86 80 79
Email: info@meditechinsights.com
Website: https://meditechinsights.com/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

This release was published on openPR.